Updates & explainers

Daraxon insights

Current regulatory context and durable scientific guides, each with a real destination and visible sources.

Company DMF update04

Nov · 2026

FDA / 2026 Q3

Q3 list: 4 APIs, 4 Type II DMFs.

DARAXONRASIB · VOPIMETOSTAT · ZOLDONRASIB · SILEVERTINIB. All four records have status A (Active). DMF numbers: 43871 · 44318 · 44304 · 44854.

DMF filings are drug master file records, not FDA marketing approvals of APIs or finished medicines.

View the four filing records →Official FDA quarterly list ↗

Regulatory update26

Aug · 2026

FDA approval

FDA approves daraxonrasib as RASONQUE for metastatic pancreatic adenocarcinoma

The approval marks a major status change for the compound long known as RMC-6236. Our update separates the approved finished medicine from research-use daraxonrasib material and links directly to FDA sources.

Read the update →

Evergreen guides

Understand the terms behind the update.

These pages are reviewed against primary sources and updated when the underlying status changes.

Compound guide

Daraxonrasib / RMC-6236

Identity, chemical data, RAS(ON) mechanism and research-material documentation.

Read guide →

Name guide

RASONQUE vs daraxonrasib

Brand, generic name, development code and clinical program—clearly mapped.

Read guide →

Biology guide

KRAS and pancreatic cancer

Why active-state RAS is important in PDAC and where daraxonrasib fits.

Read guide →